WO2003063767A3 - Rsv proteins, antibodies, compositions, methods and uses - Google Patents

Rsv proteins, antibodies, compositions, methods and uses Download PDF

Info

Publication number
WO2003063767A3
WO2003063767A3 PCT/US2002/034154 US0234154W WO03063767A3 WO 2003063767 A3 WO2003063767 A3 WO 2003063767A3 US 0234154 W US0234154 W US 0234154W WO 03063767 A3 WO03063767 A3 WO 03063767A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies
rsv
compositions
rsv proteins
Prior art date
Application number
PCT/US2002/034154
Other languages
French (fr)
Other versions
WO2003063767A2 (en
Inventor
Bernard Scallon
Original Assignee
Centocor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor filed Critical Centocor
Priority to JP2003563463A priority Critical patent/JP2005522996A/en
Priority to EP02806688A priority patent/EP1501870A4/en
Priority to MXPA04004224A priority patent/MXPA04004224A/en
Priority to AU2002365925A priority patent/AU2002365925A1/en
Priority to CA002466025A priority patent/CA2466025A1/en
Publication of WO2003063767A2 publication Critical patent/WO2003063767A2/en
Publication of WO2003063767A3 publication Critical patent/WO2003063767A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to at least one novel RSV proteins, antibodies, including isolated nucleic acids that encode at least one RSV protein or antibody, RSV vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
PCT/US2002/034154 2001-11-02 2002-10-26 Rsv proteins, antibodies, compositions, methods and uses WO2003063767A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003563463A JP2005522996A (en) 2001-11-02 2002-10-26 RSV proteins, antibodies, compositions, methods and uses
EP02806688A EP1501870A4 (en) 2001-11-02 2002-10-26 Rsv proteins, antibodies, compositions, methods and uses
MXPA04004224A MXPA04004224A (en) 2001-11-02 2002-10-26 Rsv proteins, antibodies, compositions, methods and uses.
AU2002365925A AU2002365925A1 (en) 2001-11-02 2002-10-26 Rsv proteins, antibodies, compositions, methods and uses
CA002466025A CA2466025A1 (en) 2001-11-02 2002-10-26 Rsv proteins, antibodies, compositions, methods and uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33608101P 2001-11-02 2001-11-02
US60/336,081 2001-11-02
US33783801P 2001-11-13 2001-11-13
US60/337,838 2001-11-13

Publications (2)

Publication Number Publication Date
WO2003063767A2 WO2003063767A2 (en) 2003-08-07
WO2003063767A3 true WO2003063767A3 (en) 2004-12-02

Family

ID=27668884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034154 WO2003063767A2 (en) 2001-11-02 2002-10-26 Rsv proteins, antibodies, compositions, methods and uses

Country Status (6)

Country Link
EP (1) EP1501870A4 (en)
JP (1) JP2005522996A (en)
AU (1) AU2002365925A1 (en)
CA (1) CA2466025A1 (en)
MX (1) MXPA04004224A (en)
WO (1) WO2003063767A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
JP5575377B2 (en) 2008-07-18 2014-08-20 シスメックス株式会社 RS virus detection kit and immunochromatography test device using anti-RS virus monoclonal antibody, and novel anti-RS virus monoclonal antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006448A1 (en) * 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO1998019704A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2401652A1 (en) * 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006448A1 (en) * 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO1998019704A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1501870A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US9409982B2 (en) 2000-10-06 2016-08-09 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Also Published As

Publication number Publication date
EP1501870A2 (en) 2005-02-02
EP1501870A4 (en) 2006-05-03
MXPA04004224A (en) 2005-03-31
WO2003063767A2 (en) 2003-08-07
JP2005522996A (en) 2005-08-04
AU2002365925A1 (en) 2003-09-02
CA2466025A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
WO2003035847A3 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2002012500A3 (en) Anti-il-12 antibodies, compositions, methods and uses
LTPA2019013I1 (en) Antibodies that recognize TNF, compositions, methods, and uses
WO2002012501A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
WO2002097048A3 (en) ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2005005604A3 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
TW200716745A (en) Anti-TNF antibodies, compositions, methods and uses
WO2004101750A3 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2005028511A3 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2003038041A3 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
WO2003047510A3 (en) Anti-tnf antibodies, compositions, methods and uses
WO2004067567A3 (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2003102017A3 (en) Anti-relp fusion antibodies, compositions, methods and uses
WO2003063767A3 (en) Rsv proteins, antibodies, compositions, methods and uses
WO2003082206A3 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
WO2003083059A3 (en) Mcp-1 mutant proteins, antibodies, compositions, methods and uses
WO2003083071A3 (en) Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
WO2005067477A3 (en) Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses
MY171238A (en) Anti-tnf antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2466025

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004224

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003563463

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002806688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002806688

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2002806688

Country of ref document: EP